NASDAQ
13.96USD
-0.14 (-1.03%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
190.1M
P/E
—
EPS
—
Beta
1.40
52W range
5.06-15.84
Day range
13.79–14.84
Open
14.55
Prev close
14.10
Volume
35.4K
Avg volume
236.4K
Dividend
0.00
IPO
2014-04-17
https://www.proactiveinvestors.com/companies/news/1096872 · 8/11/2026+0.60
https://www.proactiveinvestors.com/companies/news/1096871 · 8/11/2026+0.00
https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-conferences-in-july-302821082.html · 7/9/2026+0.10
https://www.proactiveinvestors.com/companies/news/1094194 · 6/19/2026+0.00
https://seekingalpha.com/article/4903109-immunic-saved-by-a-200-million-private-placement · 5/12/2026-0.20
https://www.proactiveinvestors.com/companies/news/1091334 · 4/28/2026+0.60
https://www.proactiveinvestors.com/companies/news/1091073 · 4/23/2026-0.20
https://www.prnewswire.com/news-releases/immunic-to-participate-in-scientific-and-medical-conferences-in-april-302736609.html · 4/9/2026+0.30
https://www.proactiveinvestors.com/companies/news/1088100/immunic-secures-400m-to-support-late-stage-ms-trials-icymi-1088100.html · 2/28/2026+0.90
https://www.prnewswire.com/news-releases/immunic-announces-closing-of-oversubscribed-private-placement-financing-302689923.html · 2/17/2026+0.80
https://www.proactiveinvestors.com/companies/news/1085442 · 1/10/2026+1.00
https://www.proactiveinvestors.com/companies/news/1085442/immunic-targets-ms-market-with-phase-3-data-icymi-1085442.html · 1/10/2026+0.90
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
